Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FCNAJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,509
Award facts
- Contract value 100% obligated
- $12,508.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $12,508.77 by the Defense Logistics Agency on September 12, 2025, for the supply of Xtandi 80 mg tablets (60 count). The delivery order, which is not set-aside designated, is scheduled for completion by September 15, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This award represents a discrete purchase order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
Xtandi (enzalutamide) is an oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialized pharmaceutical products to Department of Defense healthcare sites. The vendor's consistent track record of delivering branded and generic prescription drugs, biologics, and medical consumables to federal agencies demonstrates its capability to meet the Defense Logistics Agency's pharmaceutical supply requirements. This award exemplifies the Defense Logistics Agency's reliance on qualified small business pharmaceutical distributors to maintain continuous availability of essential medications across the military health system.
Quick answers
Who was awarded contract SPE2DB25FCNAJ?
SPE2DB25FCNAJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 12, 2025.
How much is contract SPE2DB25FCNAJ worth?
The government has obligated $12,509 on SPE2DB25FCNAJ.
Is contract SPE2DB25FCNAJ an order under another contract?
Yes. SPE2DB25FCNAJ is a delivery order under SPE2DB24D9144, an indefinite delivery contract.
Was contract SPE2DB25FCNAJ competed?
The extent of competition for SPE2DB25FCNAJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award